Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews to Cut 40 Percent of Canadian Workforce

NEW YORK (GenomeWeb News) – GeneNews said today that it has undertaken a restructuring of its North American and Asian operations that will result in the firm cutting its workforce in Canada, where it has its headquarters, by 40 percent.
The firm said that its Canadian operations would focus on Canadian and US commercialization of its lead product, ColonSentry, a genomics-based test for determining a person’s risk for colorectal cancer. It said that R&D activities, including patient sample accrual, will be moved to its operations in Asia.
As of March 20, GeneNews had 43 full-time employees, 2 part-time employees, 2 contract employees, 1 co-op student, and 1 consultant
"While these actions are difficult, when assessing the structure of our company and our strengths in Canada and Asia, we determined that there were efficiencies in research and development that could be better leveraged from our Asian operations in Penang, Malaysia and Tianjin, China," said Heiner Dreismann, lead director and interim CEO of GeneNews.
"Transferring this segment of our operations to our Asian facilities also enhances opportunities to access to capital from Asian sources, which GeneNews has successfully secured in the past, to support research and development activities including the accrual of patient samples to support our pipeline development,” he added.
The firm is in the process of launching the test in Canada and is gearing up for an expected US launch in the second half of 2009.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.